待处理
入排:排除
图源:待检查
Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications': [Annals of Oncology 34 (2023) p693-702].
M Burotto, Z Zvirbule, A Mochalova, Y Runglodvatana, L Herraez-Baranda, S N Liu, P Chan, E Shearer-Kang, X Liu, N Tosti, J A Zanghi, B Leutgeb, E Felip
Ann Oncol 35(5) 482
摘要
摘要
无摘要
KM 提取结果
0 个 Figure · 0 个 KM 面板